cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Xbiotech Inc
6 own
14 watching
Current Price
$3.67
$-0.18
(-4.68%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
200.45M
52-Week High
52-Week High
9.96000
52-Week Low
52-Week Low
3.51000
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
0.131961
P/E Ratio
P/E Ratio
--
iconMarket Capitalization200.45M
icon52-Week High9.96000
icon52-Week Low3.51000
iconAverage Volume0.03M
iconDividend Yield0.131961
iconP/E Ratio--
What does the Xbiotech Inc do?
XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.
Read More
How much money does Xbiotech Inc make?
News & Events about Xbiotech Inc.
Globe Newswire
1 year ago
Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after StrokeAUSTIN, Texas, April 17, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) has enrolled the first subject in a randomized, open-label, placebo-controlled dose escalation clinical study to ...
Globe Newswire
2years ago
INCA funded Phase I/II/III Study for Natrunix in Combination with Trifluridine/Tipiracil, the TASKIN Study, Launches at 20 Leading Medical Centers in FranceAUSTIN, Texas, Oct. 13, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announcedtoday the enrollment of the first patient in a multicenter, ...
Globe Newswire
2years ago
Novel Natrunix Treatment Shows Promise in Combination Chemotherapy for Treatment of Pancreatic CancerAUSTIN, Texas, June 20, 2022 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today it successfully completed the Phase I portion of its 1-BETTER study, a Phase I/II randomized, double-...
Globe Newswire
2years ago
ANSM approves NATRUNIX for INSA funded Phase-I-III Study at 20 Leading Medical Centers in FranceAUSTIN, Texas, April 28, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announcedtoday that the French National Agency for the Safety of Medicines and Health Products [L'Agence nationale de scurit du ...
Frequently Asked Questions
Frequently Asked Questions
What is Xbiotech Inc share price today?
plus_minus_icon
Can Indians buy Xbiotech Inc shares?
plus_minus_icon
How can I buy Xbiotech Inc shares from India?
plus_minus_icon
Can Fractional shares of Xbiotech Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Xbiotech Inc stocks?
plus_minus_icon
What is today’s traded volume of Xbiotech Inc?
plus_minus_icon
What is today’s market capitalisation of Xbiotech Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Xbiotech Inc?
plus_minus_icon
What percentage is Xbiotech Inc down from its 52-Week High?
plus_minus_icon
What percentage is Xbiotech Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$3.67
$-0.18
(-4.68%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$65.84
$1.82 (2.84 %)
Bioventus Inc
Bioventus Inc
$8.86
$-0.30 (-3.28 %)
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$0.59
$-0.01 (-0.84 %)
DBV Technologies S.A. - Spons-ADR
DBV Technologies S.A. - Spons-ADR
$4.65
$-0.76 (-14.05 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$65.84
$1.82 (2.84 %)
Bioventus Inc
Bioventus Inc
$8.86
$-0.30 (-3.28 %)
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$0.59
$-0.01 (-0.84 %)
DBV Technologies S.A. - Spons-ADR
DBV Technologies S.A. - Spons-ADR
$4.65
$-0.76 (-14.05 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00